Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Phakic lens holds promise for correcting high myopia, hyperopia
Philadelphia-Patients with high myopia and high hyperopia seemed to have a good response to the implantation of the Phakic Refractive Lens (PRL, Medennium Inc.), according to Kenneth J. Hoffer, MD, who reported on the phase III trial for myopia and the phase II trial for hyperopia during the American Society of Cataract and Refractive Surgery meeting here.
Related Videos
Related Content
